Introduction: Nowadays, the resection of submucosal myomas is usually performed by hysteroscopy. No previous study has investigated the use of preoperative hormonal therapy before outpatient hysteroscopic myomectomy. Objective: To compare the usefulness of 3-month preoperative treatment with ulipristal acetate (UPA) before outpatient hysteroscopic myomectomy in patients with FIGO (International Federation of Gynecology and Obstetrics) type 0–1 myomas. Study Design: This prospective patient preference study included women requiring hysteroscopic resection of single FIGO type 0–1 myoma with the largest diameter <2 cm. Patients underwent either preoperative treatment with UPA (5 mg/day) for 3 months or direct surgery. Outpatient myomectomy was performed using the bipolar electrosurgical Versapoint system (Ethicon Gynecare, USA). The primary objective of the study was to compare the rate of complete resections in the 2 study groups. The secondary objective of the study was to compare the operative time and the volume of fluid infused/absorbed. The tertiary objective of the study was to assess the surgical appearance of the myomas in patients treated with UPA. Results: The study included 38 women treated with UPA and 45 women who underwent direct surgery. UPA treatment significantly decreased the volume of uterine myomas (p < 0.001). The percentage of complete resection was higher in patients treated with UPA (89.5%) than in those who underwent direct surgery (68.9%; p = 0.046). Preoperative UPA treatment decreased the operative time (p < 0.001) and the volume of fluid infused (p = 0.016), but it did not significantly affect the volume of fluid absorbed (p = 0.874). The texture of the myoma was not significantly affected by UPA treatment (p = 0.142). Conclusions: Three-month UPA treatment improves the chance of single-step complete outpatient hysteroscopic resection of single FIGO type 0–1 myoma. Future randomized studies with a larger sample size should confirm these preliminary findings.

Keywords:
Hysteroscopy, Uterine myoma, Hysteroscopic myomectomy, Ulipristal acetate, Versapoint
1.
Lasmar RB, Lasmar BP. The role of leiomyomas in the genesis of abnormal uterine bleeding (AUB).
Best Pract Res Clin Obstet Gynaecol
. 2017 Apr;40:82–8.
2.
Russo M, Suen M, Bedaiwy M, Chen I. Prevalence of Uterine Myomas Among Women with 2 or More Recurrent Pregnancy Losses: A Systematic Review.
J Minim Invasive Gynecol
. 2016 Jul-Aug;23(5):702–6.
3.
Friedman JA, Wong JM, Chaudhari A, Tsai S, Milad MP. Hysteroscopic myomectomy: a comparison of techniques and review of current evidence in the management of abnormal uterine bleeding.
Curr Opin Obstet Gynecol
. 2018 Aug;30(4):243–51.
4.
Muzii L, Boni T, Bellati F, Marana R, Ruggiero A, Zullo MA, et al. GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study.
Fertil Steril
. 2010 Sep;94(4):1496–9.
5.
Mavrelos D, Ben-Nagi J, Davies A, Lee C, Salim R, Jurkovic D. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo-controlled randomized trial.
Hum Reprod
. 2010 Sep;25(9):2264–9.
6.
Kamath MS, Kalampokas EE, Kalampokas TE. Use of GnRH analogues pre-operatively for hysteroscopic resection of submucous fibroids: a systematic review and meta-analysis.
Eur J Obstet Gynecol Reprod Biol
. 2014 Jun;177:11–8.
7.
Agency EM. Esmya 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/esmya.
8.
Bizzarri N, Ghirardi V, Remorgida V, Venturini PL, Ferrero S. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study.
Eur J Obstet Gynecol Reprod Biol
. 2015 Sep;192:22–6.
9.
Ferrero S, Racca A, Tafi E, Alessandri F, Venturini PL, Leone Roberti Maggiore U. Ulipristal Acetate Before High Complexity Hysteroscopic Myomectomy: A Retrospective Comparative Study.
J Minim Invasive Gynecol
. 2016 Mar-Apr;23(3):390–5.
10.
Sancho JM, Delgado VS, Valero MJ, Soteras MG, Amate VP, Carrascosa AA. Hysteroscopic myomectomy outcomes after 3-month treatment with either Ulipristal Acetate or GnRH analogues: a retrospective comparative study.
Eur J Obstet Gynecol Reprod Biol
. 2016 Mar;198:127–30.
11.
Murji A, Wais M, Lee S, Pham A, Tai M, Liu G. A Multicenter Study Evaluating the Effect of Ulipristal Acetate during Myomectomy.
J Minim Invasive Gynecol
. 2018 Mar - Apr;25(3):514–21.
12.
Florio P, Filippeschi M, Imperatore A, Mereu L, Franchini M, Calzolari S, et al. The practicability and surgeons’ subjective experiences with vaginal danazol before an operative hysteroscopy.
Steroids
. 2012 Apr;77(5):528–33.
13.
Laganà AS, Giacobbe V, Triolo O, Granese R, Ban Frangež H, Vrtačnik-Bokal E, et al. Dienogest as preoperative treatment of submucous myomas for hysteroscopic surgery: a prospective, randomized study.
Gynecol Endocrinol
. 2016;32(5):408–11.
14.
Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Expert Opin Drug Metab Toxicol
. 2018 Jan;14(1):107–16.
15.
Bettocchi S, Ceci O, Di Venere R, Pansini MV, Pellegrino A, Marello F, et al. Advanced operative office hysteroscopy without anaesthesia: analysis of 501 cases treated with a 5 Fr. bipolar electrode.
Hum Reprod
. 2002 Sep;17(9):2435–8.
16.
Czuczwar P, Wozniak S, Szkodziak P, Milart P, Wozniakowska E, Wrona W, et al. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study.
Ultrasound Obstet Gynecol
. 2015 Jun;45(6):744–50.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.